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Patients’ and physicians’ disagreement on
patients’ understanding of clinical cancer
trial information: a pairwise pilot study of
mirroring subjective assessments compared
with objective measurements
Pia Dellson1* , Christina Carlsson1, Mef Nilbert1,2,3 and Helena Jernström1
Abstract
Background: Informed consent is a prerequisite for patients included in clinical trials. Trial design, inclusion criteria
and legal requirements are increasingly complex. This complexity challenges design and delivery of written and oral
trial information to ensure understandable information. To evaluate the level of concordance between patients’ and
informing physicians’ assessments regarding patient understanding of trial information, we carried out a study
based on paired questionnaire data from patients and their physicians. These assessments of patient understanding
were further correlated with patients’ factual knowledge of the information provided.
Methods: This pilot study included patients and physicians immediately after the patients had received information
on one of 23 ongoing phase III randomised cancer trials at two Swedish sites. In total, 46 patients and 17 physicians
contributed data based on two new questionnaires with seven mirroring questions, where concordance was
analysed with McNemar’s test. These assessments of patients’ self-estimated understanding were further correlated
with the Patient Understanding of Research (Q-PUR) questionnaire that assesses factual knowledge of the information
provided.
Results: For each question, 47–61% of the patient–physician pairs were in concordance regarding their assessments of
patients’ ‘fully understanding’ or ‘not fully understanding’ various aspects of the trial information. For the discordant
pairs, the physicians rated patient understanding lower than the patients themselves, for all seven questions. This
difference was significant for five of the questions (P≤ 0.017). The median Q-PUR knowledge score was 11 out of 12,
but this score did not significantly correlate with the assessments, either from patients or from physicians.
Conclusions: This study demonstrated a trend for physicians to rate the level of understanding of trial information
among potential trial patients lower than the patients themselves. Application of Q-PUR revealed high knowledge
scores, but without correlation to the assessments. These findings need validation in an independent setting, with an
improved instrument with mirroring questions, and a better-matched measurement of patients’ factual knowledge.
These results suggest that physicians need to improve their ability to assess patient understanding of clinical trial
information, in order to be able to tailor the patients’ information individually.
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Background
Clinical trials are a mainstay of medical research and
crucial to improving future health care services. Prior to
inclusion into a clinical trial, the patient must provide
informed consent, defined in the Declaration of Helsinki
[1]. The purpose of the oral and written patient informa-
tion is to convey information that enables the patient to
reach a level of understanding from which a decision
can be taken based on study design, impact and risk-
benefit combined with the patient’s individual prefer-
ences. In oncology as well as in other medical specialties,
however, the trial information is often extensive and its
communication is a complex process, which may indeed
counteract the actual intent of complete information
and full understanding [2–4].
The main responsibility for informing the patient lies
with the clinical trial team, which typically consists of
the responsible physician and a research nurse. To opti-
mise the possibility for truly informed consent, informa-
tion needs to be tailored to the individual patient.
Proper tailoring of information requires assessment of
patients’ understanding of the oral and written informa-
tion [5, 6]. However, there is limited information on how
accurate physicians’ perceptions are with respect to pa-
tients’ understanding. A study by Olson and Windish [7]
suggested that significant discrepancies exist between
how patients and physicians rated patient knowledge,
with physicians overestimating patient knowledge.
Whether this is also the case with clinical trial informa-
tion is, to our knowledge, unknown.
A large number of attempts have been made to im-
prove patients’ understanding of both written and oral
clinical trial information, as reviewed in [8–11]. The
three main forms of interventions tested are multi-
media, enhanced consent forms, and prolonged consent
discussions. Multi-media interventions have only been
shown to improve patient understanding to a limited de-
gree, whereas enhanced consent forms and prolonged
consent discussions were deemed to be the most effect-
ive interventions [8, 9]. However, in many studies the
development process of interventions and outcome mea-
sures were poorly described [10]. Thus, more research is
warranted on these topics. Several studies have shown
that patients overestimate their factual knowledge about
clinical trials. In a study by Biedrzycki [12] 72% of the pa-
tients answered ‘yes’ to the question ‘Do you basically
understand the research study?’ but only 35% had adequate
actual research knowledge as measured by the Seven-Item
Knowledge Scale, developed by Ellis et al. [13].
Another study, by Joffe et al. [14], used the validated
instrument ‘Quality of Informed Consent’ (QuIC), which
measures both perceived understanding and factual
knowledge about clinical trials, with questions directed
to patients. This study found a weak but statistically
significant correlation between patients’ factual know-
ledge and their self-assessment scores, measured by 14
questions. Furthermore, in the study another question-
naire was sent to each patient’s physician, including one
question on the physician’s estimate of the patient’s un-
derstanding. Here, a weak but statistically significant
correlation was found between physicians’ rating of the
patient’s understanding and the patient’s factual know-
ledge. This is, to our knowledge, the only study that car-
ried out pairwise comparisons between patient and
physician ratings of patient understanding of clinical tri-
als and their correlation with the patient’s factual
knowledge.
To our knowledge, there is a lack of direct compari-
sons between patients’ own assessments of their under-
standing of the clinical trial information and physicians’
assessments of their patients’ understanding. The main
purpose of this exploratory pilot study was to investigate
how patients invited to take part in a clinical cancer trial
rated their own understanding of the clinical trial infor-
mation, and to compare the results with the paired phys-
ician assessments of patient understanding. A secondary
purpose was to correlate these assessments with pa-
tients’ factual knowledge of the oral and written clinical
trial information provided.
Methods
Setting, participants, and data collection
Between January 2009 and February 2013, 46 paired
questionnaires for patients and physicians were col-
lected, and 100% of the distributed questionnaires were
returned. There was no recording of patients or physi-
cians declining to participate when invited. Forty-six pa-
tients and 17 physicians were included. Each physician
could participate a maximum number of five times in
the study. The study was conducted at two Swedish
sites, Lund and Malmö. Patients who could read and
speak Swedish and who were eligible for 23 selected
clinical cancer trials were included. The selection criteria
for the clinical trials were that the trials should be ran-
domised phase III trials that were expected to include
patients for at least one year. Furthermore, the trial had
to have a research nurse responsible for handing out the
questionnaires. The trials concerned treatment for 14
different cancer diagnoses with both curative and pallia-
tive intention (Table 1). It was not recorded which trial
the patient was offered, or whether they accepted or de-
clined participation.
Informed consent was obtained from all participants.
The study was approved by the Lund University Ethics
Committee (Dnr 346/2007).
A study design with paired questionnaires was used,
one questionnaire for the patient receiving information
and another questionnaire for the informing physician.
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The patients completed the questionnaire directly after
they had received the oral and written patient informa-
tion on the clinical cancer trial they were about to con-
sider participation in. The physicians completed their
questionnaire directly after the consultation when they
had informed the patient about the clinical trial.
Questionnaires
The study comprised two questionnaires, one for patients
and one for physicians. The patient questionnaire was
composed of the following three sections: 1) demographic
information; 2) patients’ assessment of perceived under-
standing, seven mirroring questions (7Q-PAT); and 3) pa-
tients’ factual knowledge measured by the Patient
Understanding of Research questionnaire (Q-PUR). The
physician questionnaire was composed of the following
two sections: 1) demographic information; and 2) physi-
cians’ assessment of their patients’ understanding, seven
mirroring questions (7Q-PHYS).
The demographic information included gender and age.
Information from additional questions about educational
level and previous participation in a clinical trial by the pa-
tient or their next of kin was also collected from patients.
Physicians were asked about the number of years spent
working in oncology, type of post, and number of patients
they had included in a clinical trial. Each physician could
participate a maximum number of five times in the study, to
avoid any single individual dominating the study material.
The section on perceived patient understanding of oral
and written information was constructed by the research
team and consisted of seven mirroring questions for pa-
tients and physicians, respectively (7Q-PAT and 7Q-
PHYS; Table 2). The seven questions on perceived pa-
tient understanding were selected based on earlier stud-
ies where key points for consideration were identified
[15–17]. The questions included separate queries on
how the patients understood the written and oral trial in-
formation respectively. During the process of designing
the questionnaire, the seven questions were tested on re-
search nurses and physicians and adjusted according to
their feedback. The questions concerned how the patients
rated their understanding of the oral and written informa-
tion, respectively, of the terms and expressions used by
the physicians orally and in the written information, of the
study treatment and follow-up, of the side effects, and of
the aim of the clinical trial (Table 2). Each question was
formulated as a statement with four possible answers: fully
agree/partly agree/do not fully agree/disagree.
Table 1 Eligible phase III clinical trials
Study name Clinical trial number Diagnosis Intention Treatment modality
ACT NCT00598156 Colorectal cancer Palliative Kinase inhibitor
ACT-1 NCT00646854 T-cell lymphoma Curative Antibody
BEATRICE NCT00528567 Breast cancer Curative Antibody
BRCATrial NCT00321633 Breast cancer Palliative Chemotherapy
COMPARZ NCT00720941 Renal cell carcinoma Palliative Kinase inhibitor
CYCLUS NCT00300729 Non-small cell carcinoma Palliative Nonsteroidal anti-inflammatory drug
ENESTg1 NCT00785785 Gastrointestinal stromal tumour Palliative Kinase inhibitor
ESPAC NCT00058201 Pancreatic cancer Curative Chemotherapy
EXAM NCT00704730 Thyroid cancer Palliative Kinase inhibitor
HYPO-RT-PC ISRCTN45905321 Prostate cancer Curative Radiation therapy
INTORSECT NCT00474786 Renal cell carcinoma Palliative Kinase inhibitor
MAIN NCT00486759 B-cell lymphoma Curative Antibody
OVAR 12 NCT01015118 Ovarian cancer Palliative Kinase inhibitor
OVAR 16 NCT01462890 Ovarian cancer Palliative Antibody
PALETTE NCT00753688 Sarcoma Palliative Kinase inhibitor
PANTHER NCT00798070 Breast cancer Curative Chemotherapy
PRELUDE NCT00332202 B-cell lymphoma Curative Kinase inhibitor
RASTEN NCT00717938 Small cell lung cancer Palliative Low molecular heparin
SOFT NCT00066690 Breast cancer Curative Endocrine
SOLD NCT00593697 Breast cancer Curative Antibody
SPRINT NCT00875667 Mantle cell lymphoma Palliative Immune modulator
START NCT00409188 Non-small cell carcinoma Palliative Vaccine
SUN1120 NCT00676650 Prostate cancer Palliative Kinase inhibitor
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In the patient questionnaire, but not in the physician
questionnaire, a third section that measured the patients’
factual knowledge of clinical trial information was in-
cluded. For this section the validated Patient Under-
standing of Research questionnaire (Q-PUR) [18] was
used. Q-PUR is a multiple-choice instrument that ob-
jectively tests the patients’ factual knowledge about clin-
ical trials [18]. The 12 Q-PUR questions are presented in
Table 3. For the complete Q-PUR instrument, see the
original paper by Hutchison [18]. Regarding reliability,
Q-PUR has been shown to have an overall questionnaire
score with an acceptable Cronbach’s alpha of 0.77 (95%
CI 0.69–0.84). The corrected item total correlation be-
tween individual questions and the overall questionnaire
score is, however, low (< 0.4) for several of the questions.
Six of the 12 questions had an item total correlation
Table 2 Patient and physician responses to seven statements regarding the patient’s understanding of the information
Patient responses Physician responses
Patient/physician questions Fully agrees
n (%)
Partly agrees
n (%)
Does not
fully agree
n (%)
Disagrees
n (%)
n Fully agrees
n (%)
Partly agrees
n (%)
Does not
fully agree
n (%)
Disagrees
n (%)
n
1. I/the patient understood the
oral information completely
38 (82.6) 8 (17.4) - - 46 26 (56.5) 20 (43.5) - - 46
2. I/the patient understood the
written information
completely
37 (80.4) 9 (19.6) - - 46 23 (51.1) 21 (46.7) 1 (2.2) - 45
3. I/the patient understood all
words and expressions that
the physician used during
the oral information
36 (78.3) 8 (17.4) 2 (4.3) - 46 24 (52.2) 22 (47.8) - - 46
4. I/the patient understood all
words and expressions in
the written information
30 (65.2) 13 (28.3) 3 (6.5) - 46 19 (42.2) 24 (53.3) 2 (4.4) - 45
5. I/the patient understood
how the treatment would
be carried out and
followed up
42 (91.3) 4 (8.7) - - 46 30 (65.2) 16 (34.8) - - 46
6. I/the patient understood
what side-effects the
treatment may have
40 (88.9) 4 (8.9) 1 (2.2) - 45 28 (60.9) 18 (39.1) - - 46
7. I/the patient understood
the purpose of the
research study
40 (87.0) 5 (10.9) 1 (2.2) - 46 33 (71.7) 10 (21.7) 3 (6.5) - 46
Table 3 Results for Q-PUR and indication of six and three selected questions
Q-PUR question Percentage of correct answers 6 questions 3 questions
1. The main reason for carrying out research with patients is… 93.5 x
2. Research with patients is carried out… 91.3 x
3. In a randomized clinical research trial/study…* 95.7 x
4. The main aim of a randomized trial is to… 97.8 x
5. When a trial is randomized… 87.0 x
6. It is justified for doctors to carry out a randomized trial… 65.2 x
7. If ‘best supportive care’ or ‘symptom control’ is one of the
randomization options in the trial, it means that…**
65.2
8. Patients are chosen for a trial… 82.6 x
9. Taking part in the trial… 95.7 x
10. You can leave a trial… 95.7
11. If you do not want to take part in a trial… 87.0 x
12. Doctors involved in clinical research trials/studies… 65.2
* In the Swedish translation the following statement was inserted after the word randomized: ‘(the patients are assigned by lot to one group or the other)’
** In the Swedish translation the words ‘best supportive care’ in English were kept in parentheses after the Swedish translation, and the words ‘symptom control’
were omitted
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above 0.4 and were deemed to most reliably measure pa-
tient understanding. These six selected questions are in-
dicated in Table 3. Separate analyses of these six
questions were also performed.
Question number 7 in the 7Q-PAT and 7Q-PHYS read
‘I/the patient understood the purpose of the research
study’. The corresponding questions measuring the pur-
pose of the study in Q-PUR were questions number 1, 4
and 6 (Table 3). In order to specifically study how well
the questionnaires correlated regarding these questions
on study purpose, separate analyses were performed be-
tween question number 7 in the 7Q-PAT and 7Q-PHYS
and questions number 1, 4 and 6 in Q-PUR. The 12 Q-
PUR questions were translated to Swedish and re-
translated to English by professional translators to en-
sure that the questionnaire would be correctly repre-
sented in Swedish.
Statistical analysis
The data were analysed using SPSS version 24.0.0.1
(IBM). For the demographic data, the number and per-
centages for each group are presented for the categorical
variables. The continuous variables, i.e. participants’ age
and number of years working as physicians in oncology,
are presented with median and range. For the physicians,
who may have included up to five patients over the
study duration of five years, the demographic data from
the first questionnaire are presented.
For the rating of patients’ perceived understanding
(7Q-PAT and 7Q-PHYS), each question could be an-
swered as one of four categories. Few participants indi-
cated ‘do not fully agree’ and none indicated ‘disagree’.
Therefore, the data were dichotomised according to
‘fully agree’ (yes/no). If either the patient or the phys-
ician in a pair had not answered a question, the pair was
discarded. McNemar’s test was used to evaluate the con-
cordance for ‘fully agree’ between each patient–physician
pair for each of the seven questions in the 7Q-PAT and
7Q-PHYS. In case of missing data for either patient or
physician, both were excluded from the pairwise
analysis.
For the 12 Q-PUR questions on patients’ factual know-
ledge, the percentage of patients indicating the correct
answer was calculated. Spearman rank correlations be-
tween the total number of correct answers for the 12
questions and ‘fully agree’ on the seven questions in the
7Q-PAT and 7Q-PHYS were calculated for patients and
physicians, respectively. Furthermore, the six Q-PUR
questions with the highest item total correlation accord-
ing to the original paper [18] and the three Q-PUR ques-
tions concerning the purpose of a clinical trial were
correlated with the number of ‘fully agree’ for the seven
questions in the 7Q-PAT and 7Q-PHYS of perceived un-
derstanding for patients and physicians, respectively.
The three Q-PUR questions concerning the purpose of
a clinical trial were selected for a separate analysis in re-
lation to question number 7 (‘I/the patient understood
the purpose of the research study’) regarding perceived
understanding of the purpose of the trial. Spearman rank
correlation was used to analyse the correlation between
number of correct answers for the three Q-PUR ques-
tions and whether or not the patients and their physi-
cians indicated that the patient ‘fully’ understood the
purpose of the trial. In addition, McNemar’s test was
used to analyse concordance between patients who ‘fully’
understood the purpose of the trial (question number 7
in the 7Q-PAT) and scored three correct answers on the
three Q-PUR questions. Similarly, a second McNemar’s
test was used to analyse concordance between physicians
who indicated that their patients ‘fully’ understood the
purpose of the trial (question number 7 in the 7Q-
PHYS) and whether or not the paired patients scored
three correct answers on the three Q-PUR questions.
The demographic factors of the patients were com-
pared with the median Q-PUR score for the 12, six and
three questions (Table 3). The dichotomous variables
(sex, previous participation in research trial either self-
experienced or via next of kin) were compared with
Mann-Whitney U-test. Age was categorised in three
groups (< 50, 50–64 and ≥ 65 years). Median Q-PUR
scores were compared between age groups and different
levels of education with Jonckheere-Terpstra Test for
Trend.
No formal a priori power calculation was carried out.
A pilot study with a minimum of 40 pairs was consid-
ered large enough to reliably quantify correlations and
associations between the various questions regarding
both patients and physicians. Statistical significance was
set at P < 0.05. All P values were two-tailed. Since this is
an exploratory study, each P value should be viewed as
the level of evidence against each null hypothesis. There-
fore, nominal P values without adjustment for multiple
testing are presented [19].
Results
The study included 46 patients, who were informed by
17 physicians. See Table 4 for characteristics of patients
and physicians in the study.
Table 2 shows the patient and physician responses
to the seven statements regarding the patients’ per-
ceived understanding of clinical trial information (7Q-
PAT and 7Q-PHYS). On a group level, between 65.2%
and 91.3% of the patients fully agreed with each state-
ment. The lowest percentage pertained to the under-
standing of the words and expressions in the written
information (question 4), and the highest percentage
pertained to how the treatment would be carried out
and followed up (question 5).
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The physicians’ ratings on a group level were lower
than their patients’ for all the questions, and the per-
centage of ‘fully agree’ ranged between 42.2 and 71.7%.
As with the patients, the lowest percentage pertained to
the patient’s understanding of the words and expressions
in the written information (question 4). However, the
highest percentage who fully agreed pertained to the
patient’s understanding of the purpose of the clinical
trial (question 7). Since only six physicians informed
three or more patients, no intra-physician scoring could
be performed.
Table 5A shows the paired analyses of the percentage of
patients and physicians who fully agree with the seven
statements regarding the patients’ perceived understanding
Table 4 Patient and physician characteristics
Patients (n = 46) Physicians (n = 17)
Number (%) or
median (range)
Number (%) or
median (range)
Gender Female 37 (80.4%) 5 (29.4%)
Male 9 (19.6%) 12 (70.6%)
Age Median age, years (range) 62 (21–76) 51 (32–65)
Educational level Compulsory school (1–9 years) 7 (15.2%) 0 (0%)
Senior high school or vocational
training (10–12 years)
16 (34.8%) 0 (0%)
College or university (13–16 years) 23 (50.0%) 17 (100%)
Participation in clinical trial Previous participation in a clinical trial 6 (13.0%) –
Next of kin has participated in a
clinical trial
4 (8.7%) –
Years working in Oncology Years (range) – 17 (3–35)
Working as Resident physician – 2 (11.8%)
Specialist in oncology – 15 (88.2%)
Number of patients included
in clinical trials
< 10 – 4 (23.5%)
10–100 – 11 (64.7%)
> 100 – 2 (11.8%)
Table 5 Percentage of patients and physicians who fully agree with the statement (A) and concordance of patients’ and physicians’
estimation of patient understanding of information (B)
A B
Patient’s/physician’s questions Patient fully
agrees (%)*
Physician fully
agrees (%)*
Number
of pairs*
Number of
concordant
pairs
Only patient
fully agrees
Only physician
fully agrees
McNemar’s
test P value
1. I/the patient understood the oral
information completely
82.6 56.5 46 26 16 4 0.012
2. I/the patient understood the written
information completely
80.0 51.1 45 26 16 3 0.004
3. I/the patient understood all words
and expressions that the physician
used during the oral information
78.3 52.2 46 24 17 5 0.017
4. I/the patient understood all words
and expressions in the written
information
64.4 42.2 45 21 17 7 0.064
5. I/the patient understood how
the treatment would be carried
out and followed up
91.3 65.2 46 28 15 3 0.008
6. I/the patient understood what
side effects the treatment
may have
88.9 60.0 45 26 16 3 0.004
7. I/ the patient understood the
purpose of the research study
87.0 71.7 46 27 13 6 0.167
*If either patient or physician had not answered the question the pair was discarded from both A and B
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(7Q-PAT and 7Q-PHYS). One patient had not answered
one of the seven questions and one physician had not an-
swered two other questions, which led to a total of one pair
for three different questions being excluded from this pair-
wise analysis. For each statement the concordance of ‘fully
agree’ was compared for the patient–physician pair (7Q-
PATand 7Q-PHYS).
Between 46.7 and 60.9% of the pairs for each question
were in concordance with respect to whether they fully
agreed with the statement or not. For the discordant
pairs, there was a higher number where only the patient
had rated ‘fully agree’, compared to the number where
only the physician had rated ‘fully agree’, for all seven
questions. This difference was significant for five of the
questions (questions number 1, 2, 3, 5 and 6; Table 5B).
Overall, there was no correlation between the number
of ‘fully agree’ for the seven questions of patients’ rating
of perceived understanding (7Q-PAT and 7Q-PHYS) and
their Q-PUR score, whether measured with 12, six or
three questions (all P values ≥ 0.47). The percentage of
correct answers for each question ranged between 65.2
and 97.8% on a group level (Table 3). Neither was there
any correlation between the physicians’ rating of a pa-
tient’s understanding and that patient’s Q-PUR know-
ledge score, whether measured with 12, six or three
questions (all P values ≥ 0.25).
The concordance between whether or not the patients
answered ‘fully agree’ on question 7 (‘I/the patient
understood the purpose of the research study’) and
scored three out of the three selected Q-PUR questions
on study purpose (n = 27) was somewhat higher than for
the physicians (n = 22). However, for discordant pairs pa-
tients were significantly more likely to overestimate ra-
ther than underestimate their understanding of the trial
in relation to their factual knowledge, as measured by
the three selected Q-PUR questions (P = 0.019). There
was no significant direction for the discordant results
between whether or not the physicians answered ‘fully
agree’ to question 7 and their patient scored three out of
three selected Q-PUR questions (P = 0.54).
To explore whether or not demographic data may
have influenced the results, these factors were compared
with the results of both the assessments (7Q-PAT and
7Q-PHYS) and the Q-PUR score. There was no signifi-
cant association between the patients’ educational level
and their rating of their understanding in 7Q-PAT
(Ptrend = 0.64), or between the patients’ educational level
and the physicians’ rating of their understanding in 7Q-
PHYS (Ptrend = 0.75). There were also no significant dif-
ferences in Q-PUR score due to gender, age or whether
the patient or a next of kin had previously participated
in a clinical trial. No attempt at sub-group analysis was
made due to small numbers. The only factor that made
a significant difference was educational level. Patients
with higher education scored significantly higher on Q-
PUR (Table 6).
Discussion
Our study demonstrates that physicians rated patients’
understanding of clinical cancer trial information lower
than the patients, and this pattern applied to all ques-
tions posed (7Q-PAT and 7Q-PHYS). Neither the pa-
tients’ nor their physicians’ ratings correlated with the
patients’ factual knowledge, as measured by Q-PUR. The
physicians and the patients agreed in their assessment of
patient understanding in about half of the patient–phys-
ician pairs for every question. When the pairs disagreed,
the patients in general rated their understanding as
higher than the physicians rated it. Thus, physicians be-
lieved that patients understood less than the patients
themselves believed.
Physician assessment of patient understanding of clin-
ical trial information, in an individual and pairwise com-
parison with patients’ own assessment of their
understanding, has to our knowledge only been investi-
gated once previously [14]. In that study, however, the
physicians were asked to assess patient understanding
globally with one question, whereas the patients com-
pleted 14 questions. In the present study, both patients
and physicians each completed seven questions that mir-
rored each other. This is a new approach that allows a
more detailed examination of problematic areas of pa-
tient understanding of clinical trial information.
Table 6 Median scores for Q-PUR questions for all patients and in relation to education level
Educational level Number of correct answers
out of 12 questions,
median (range)*
Number of correct answers
out of six selected questions,
median (range)*
Number of correct answers
out of three selected questions,
median (range)*
All 11 (4–12) 6 (1–6) 3 (1–3)
Compulsory school 9 (4–11) 5 (1–6) 2 (1–3)
Senior high school 10.5 (6–12) 6 (3–6) 3 (1–3)
College or university 11 (9–12) 6 (4–6) 3 (2–3)
P value** 0.001 0.004 0.012
* See Table 3 for the list of the 12, 6, and 3 Q-PUR questions
** Jonckheere-Terpstra Test for Trend
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The present study showed that physicians assess pa-
tients’ knowledge lower than the patients’ do. One rea-
son may be that the physicians were more cautious than
the patients in scoring full understanding of the infor-
mation since this is a high standard to meet. Physicians
may also be conscious of a number of details that they
have not informed the patient about because of lack of
time or information overload for the patient or because
the physician deemed these details to be less important.
Patients, on the other hand, may be unaware of what
facts they do not know, and therefore consider them-
selves to understand completely.
Furthermore, there was no definition of what ‘fully’
agree implied compared to ‘partly’ or ‘not fully’ agree,
which might have impacted on the results [20]. This
constitutes a limitation. The groups ‘partly’ and ‘not
fully’ were merged for statistical reasons, which made
this problem smaller. However, the lack of a definition
for ‘fully’ understand might still be a problem. On the
other hand, the vast majority of patients considered that
they fully understand the information regarding all the
subjective questions (7Q-PAT), and the scores for factual
knowledge as measured by Q-PUR were high for almost
all of them. None of the patients or physicians had indi-
cated ‘disagree’, which was the lowest alternative for level
of understanding. Altogether, this may be considered to
reflect an adequate level of understanding and know-
ledge. Moreover, there exists no consensus in the litera-
ture of what is ‘good enough’ patient understanding for
being able to make an informed decision on participa-
tion in a clinical cancer trial [21]. The aim is often de-
scribed as true or completely informed consent, but this
may not be a realistic goal.
In order to evaluate whether the ratings of the pa-
tients’ understanding were correct, an objective meas-
urement of the patients’ factual knowledge was
warranted. There were a limited number of validated,
non-trial-specific questionnaires available for cancer at
the time the pilot study was planned. The two most rele-
vant questionnaires were the ‘Quality of Informed Con-
sent’ (QuIC) [22] and the ‘Questionnaire—Patient
Understanding of Research’ (Q-PUR) [18]. The QuIC in-
cludes sections for patients on both perceived under-
standing (14 questions) and factual knowledge (20
questions). However, the QuIC has no mirroring ques-
tions for physicians, which was an important part of the
present study. The 14 QuIC patient questions on per-
ceived understanding were deemed too extensive to be
converted into mirroring questions for physicians. To
keep the number of questions down, Q-PUR was chosen.
In the present study, the feasibility and acceptability of
the questionnaires were high, and 100% of the question-
naires were returned by patients and physicians. This
high return rate was probably due to the small number
of patients included in the pilot study, as well as the
small scale of the two research sites. The fact that pa-
tients had their own personal research nurse who could
remind them if they forgot to return the questionnaires
probably also contributed to the high return rate.
However, this study gives no support to a correlation
between the questions regarding perceived patient un-
derstanding (7Q-PAT and 7Q-PHYS) and the factual
knowledge questionnaire (Q-PUR). A reason for this
finding could be that the content of the questions re-
garding perceived understanding (7Q-PAT and 7Q-
PHYS) does not fully match the Q-PUR questions.
Questions 1–4 can be argued to be general enough to
match the Q-PUR as a whole (Table 2). Questions 5 and
6 in particular do not have any directly corresponding
Q-PUR questions. Only question 7 (‘I/the patient under-
stood the purpose of the research study’) has three spe-
cific equivalent Q-PUR questions (questions 1, 4 and 6).
Q-PUR as a whole does not give a direct answer to the
subjective questions in this study (7Q-PAT and 7Q-
PHYS) and may not be sufficiently correlated to be a
useful measure of factual knowledge in this context.
The only demographic factor associated with the Q-
PUR score was education. A higher educational level
was significantly associated with a higher Q-PUR score,
which is in line with Hutchison’s results when testing
the instrument [18]. Other studies using different instru-
ments have also shown an association between educa-
tional level and knowledge [12, 14, 23, 24]. On the other
hand, in two studies using the QuIC, a higher education
was not associated with better scores [25, 26].
The recruitment window spanned over 4 years. Poten-
tial reasons for this long time span are that the study
was conducted at two relatively small sites, where each
physician was only allowed to participate with five pa-
tients, which impaired recruitment speed. Further,
changes of research nurses may have contributed to the
slow recruitment. Since this was an exploratory pilot
study, the number of participants was small, which
makes it harder to achieve statistical significance, and no
formal a priori power calculation was carried out. Nom-
inal P values were presented without adjustment for
multiple testing, which may have led to false positive
findings, and the findings must therefore be validated in
an independent setting [19].
Considering the generalisability of the findings of this
study, cancer patients are recruited to clinical trials both
in the palliative and in curative/adjuvant settings. This
pilot study therefore included clinical trials with a wide
range of different diagnoses and settings, in order to
capture all different aspects. Since there was no informa-
tion on the specific trial each patient had been offered, it
was not possible to elucidate whether patient under-
standing differed between the palliative and the curative/
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adjuvant settings. Further, no information on whether
they accepted or declined participation was available.
These issues may be addressed if a larger study is to be
conducted. However, the aim of the study was to investi-
gate patient understanding of clinical trial information,
irrespective of type of trial and participation outcome.
Further, 70% of the physicians were male, while 80% of
the patients were female. The high proportion of female
patients reflects the fact that breast and ovarian cancer
trials were most actively recruiting patients at the time
of this study, although several different cancer types
were covered. The education level of the patients was
high, and 50% of them had a college education, which
may reflect the fact that Lund is a University town. For
Sweden as a whole, 27% of the population has a univer-
sity education [27]. Malmö is the third largest city in
Sweden with a wide range of socio-economic back-
grounds. There are many highly educated people as well
as many immigrants with various degrees of education,
but as the patients had to be able to speak and read
Swedish to be included in this study there were no non-
Swedish-speaking patients. These facts suggest there
may be a bias towards inclusion of better-educated
Swedish-speaking female patients. Further, we have no
data on patients who were never invited to participate in
the study. These patients may differ from those who the
research nurse decided to approach, whereof all agreed
to participation. Our sample may therefore not be gener-
alisable to the underlying population of cancer patients.
Although the new questionnaires with mirroring ques-
tions were not validated (7Q-PAT and 7Q-PHYS), the
content validity was addressed in several ways. Firstly, we
chose the questions based on the results from our previ-
ous research exploring patients’ preferences [15, 16].
Thereafter, research nurses and physicians tested the
questionnaire, and the questions were adjusted according
to their feedback. Regarding the Q-PUR, the English ver-
sion of Q-PUR is validated and tested for reliability [18],
although the Swedish version of the questionnaire is not.
Furthermore, the translation process may have benefitted
from also using, for example, the EORTC quality of life
group translation procedure [28].
Taken together, this exploratory pilot study had limita-
tions in different areas, such as limited study size, gen-
der and educational imbalance between patients and
physicians on a group level, and a non-validated ques-
tionnaire. However, the study has several strengths. The
time between information disclosure and measurement
of understanding was very short. Usually it took place
immediately after the information disclosure for both
patients and physicians. This ensured that the risk of
memory errors was minimised, which is particularly im-
portant for the physicians who include many patients in
trials. The greatest strength may be that the patient and
physician questionnaires (7Q-PAT and 7Q-PHYS) had
mirroring questions and were collected pairwise, which
enabled paired analyses. To our knowledge, only one
previous study has investigated physicians’ assessment of
patient understanding of research [14]. This research
field thus needs to be further elucidated.
Our results indicate a gap between patients’ perceived
understanding and physicians’ assessment of patient under-
standing. Studies have also shown that patients may base
their decision to participate in a clinical trial on inadequate
facts and misunderstandings [4, 29, 30], although they con-
sider themselves to understand the trial information. In
order to improve patient understanding of clinical trials,
several kinds of interventions have been shown to be effect-
ive: enhanced consent documents, decisional aids and ex-
tended consent conversations seem to be of particular
interest [9, 31]. To optimise the informed consent process,
the physicians need to assess better what each patient un-
derstands in order to tailor their information better and in-
dividually. To achieve this tailoring and to minimise the
gap between patients’ perceived understanding and physi-
cians’ assessment of their patients’ understanding, physi-
cians need to improve their communication skills [32, 33].
Conclusions
This exploratory pilot study indicates a gap between pa-
tients and physicians, where the physicians rated their
patients’ understanding lower than the patients them-
selves for all questions on subjective understanding.
However, neither the patients’ nor their physicians’ rat-
ings were correlated with the patients’ factual know-
ledge, as measured by Q-PUR. These findings need
validation in an independent setting, with an improved
instrument with mirroring questions and a better-
matched measurement of patients’ factual knowledge.
Nevertheless, these results suggest that physicians need
to improve their ability to assess patient understanding
of clinical trial information, in order to be able to tailor
the patient information individually.
Abbreviations
Q-PUR: Questionnaire—Patient Understanding of Research; QuIC: Quality of
Informed Consent; SPSS: Statistical Package for the Social Sciences
Acknowledgements
We are most grateful to the patients and colleagues who participated in this
project. We would also like to thank Professor Kerstin Nilsson for insightful
comments on the manuscript.
Authors’ contributions
PD: study design, data collection, data base design, data analysis, interpretation
of data analysis, and drafting the manuscript. CC: study design, data collection,
and drafting the manuscript. MN: study design and drafting the manuscript. HJ:
data base design, data analysis, interpretation of data analysis, and drafting the
manuscript. All authors read and approved the final manuscript.
Authors’ information
PD: MD, senior consultant in oncology and psychiatry, PhD candidate.
Dellson et al. Trials          (2019) 20:301 Page 9 of 10
CC: PhD, study nurse with extensive experience in qualitative studies and
patient preferences and involvement.
MN: MD, PhD, senior consultant and professor in oncology.
HJ: PhD, Professor in experimental oncology with focus on integrative cancer
epidemiology.
Funding
Financial support was granted by the Gunnar Nilsson Cancer Fund, the Region
Skane Research Fund, the Faculty of Medicine at Lund University, and Region
Skane ALF.
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available.
Ethics approval and consent to participate
Informed consent was obtained from all participants. The study was
approved by the Lund University Ethics Committee (Dnr 346/2007).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Clinical Sciences in Lund, Division of Oncology, Lund
University and Skåne University Hospital, Barngatan 4, 221 85 Lund, Sweden.
2Clinical Research Center, Copenhagen University Hospital, Hvidovre,
Denmark. 3Danish Cancer Society Research Center, Copenhagen, Denmark.
Received: 11 January 2019 Accepted: 8 May 2019
References
1. WMA. World Medical Association Declaration of Helsinki: ethical principles
for medical research involving human subjects. JAMA. 2013;310:2191–4.
2. Cox K. Informed consent and decision-making: patients' experiences of the
process of recruitment to phases I and II anti-cancer drug trials. Patient
Educ Couns. 2002;46:31–8.
3. Jenkins V, Solis-Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ. What
oncologists believe they said and what patients believe they heard: an
analysis of phase I trial discussions. J Clin Oncol. 2011;29:61–8.
4. Dellson P, Nilsson K, Jernstrom H, Carlsson C. Patients' reasoning regarding
the decision to participate in clinical cancer trials: an interview study. Trials.
2018;19:528.
5. Jefford M, Moore R. Improvement of informed consent and the quality of
consent documents. Lancet Oncol. 2008;9:485–93.
6. del Carmen MG, Joffe S. Informed consent for medical treatment and
research: a review. Oncologist. 2005;10:636–41.
7. Olson DP, Windish DM. Communication discrepancies between physicians
and hospitalized patients. Arch Intern Med. 2010;170:1302–7.
8. Flory J, Emanuel E. Interventions to improve research participants'
understanding in informed consent for research: a systematic review. JAMA.
2004;292:1593–601.
9. Nishimura A, Carey J, Erwin PJ, Tilburt JC, Murad MH, McCormick JB.
Improving understanding in the research informed consent process: a
systematic review of 54 interventions tested in randomized control trials.
BMC Med Ethics. 2013;14:28.
10. Kao CY, Aranda S, Krishnasamy M, Hamilton B. Interventions to improve
patient understanding of cancer clinical trial participation: a systematic
review. Eur J Cancer Care (Engl). 2017;26:1–13.
11. Nathe JM, Krakow EF. The challenges of informed consent in high-stakes,
randomized oncology trials: a systematic review. MDM Policy Pract. 2019;4:
2381468319840322.
12. Biedrzycki BA. Research information knowledge, perceived adequacy, and
understanding in cancer clinical trial participants. Oncol Nurs Forum. 2011;
38:E291–6.
13. Ellis PM, Butow PN, Tattersall MH, Dunn SM, Houssami N. Randomized
clinical trials in oncology: understanding and attitudes predict willingness to
participate. J Clin Oncol. 2001;19:3554–61.
14. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent
in cancer clinical trials: a cross-sectional survey. Lancet. 2001;358:1772–7.
15. Dellson P, Nilbert M, Bendahl PO, Malmstrom P, Carlsson C. Towards
optimised information about clinical trials; identification and validation of
key issues in collaboration with cancer patient advocates. Eur J Cancer Care
(Engl). 2011;20:445–54.
16. Dellson P, Nilbert M, Carlsson C. Patient representatives' views on patient
information in clinical cancer trials. BMC Health Serv Res. 2016;16:36.
17. Cox AC, Fallowfield LJ, Jenkins VA. Communication and informed consent in
phase 1 trials: a review of the literature. Support Care Cancer. 2006;14:303–9.
18. Hutchison C, Cowan C, Paul J. Patient understanding of research:
developing and testing of a new questionnaire. Eur J Cancer Care (Engl).
2007;16:187–95; quiz 95-6.
19. Bender R, Lange S. Adjusting for multiple testing--when and how? J Clin
Epidemiol. 2001;54:343–9.
20. Schaeffer N. Hardly ever or constantly. Group comparisons using vague
quantifiers. Public Opin Q. 1991;55:395–423.
21. Sand K, Kaasa S, Loge JH. The understanding of informed consent
information—definitions and measurements in empirical studies. AJOB Prim
Res. 2010;1:4–24.
22. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent:
a new measure of understanding among research subjects. J Natl Cancer
Inst. 2001;93:139–47.
23. Miller CK, O'Donnell DC, Searight HR, Barbarash RA. The Deaconess
Informed Consent Comprehension Test: an assessment tool for clinical
research subjects. Pharmacotherapy. 1996;16:872–8.
24. Cameron P, Pond GR, Xu RY, Ellis PM, Goffin JR. A comparison of patient
knowledge of clinical trials and trialist priorities. Curr Oncol. 2013;20:e193–205.
25. Bergenmar M, Johansson H, Wilking N. Levels of knowledge and perceived
understanding among participants in cancer clinical trials - factors related to
the informed consent procedure. Clin Trials. 2011;8:77–84.
26. Brandberg Y, Johansson H, Bergenmar M. Patients' knowledge and
perceived understanding - Associations with consenting to participate in
cancer clinical trials. Contemp Clin Trials Commun. 2016;2:6–11.
27. Educational attainment of the population in 2017 [http://www.scb.se/en/
finding-statistics/statistics-by-subject-area/education-and-research/
education-of-the-population/educational-attainment-of-the-population/
pong/statistical-news/educational-attainment-of-the-population-in-2017/].
Accessed 10 Dec 2018.
28. EORTC quality of life group translation procedure [http://www.eortc.org/
app/uploads/sites/2/2018/02/translation_manual_2017.pdf]. Accessed 10
Dec 2018.
29. Behrendt C, Golz T, Roesler C, Bertz H, Wunsch A. What do our patients
understand about their trial participation? Assessing patients' understanding
of their informed consent consultation about randomised clinical trials. J
Med Ethics. 2011;37:74–80.
30. Bergenmar M, Molin C, Wilking N, Brandberg Y. Knowledge and
understanding among cancer patients consenting to participate in clinical
trials. Eur J Cancer. 2008;44:2627–33.
31. Sundaresan P, Ager B, Turner S, Costa D, Kneebone A, Pearse M, Woo H,
Tesson S, Juraskova I, Butow P. A randomised controlled trial evaluating the
utility of a patient Decision Aid to improve clinical trial (RAVES 08.03) related
decision-making. Radiother Oncol. 2017;125:124–9.
32. Wade J, Donovan JL, Lane JA, Neal DE, Hamdy FC. It's not just what you
say, it's also how you say it: opening the 'black box' of informed consent
appointments in randomised controlled trials. Soc Sci Med. 2009;68:2018–28.
33. Hietanen PS, Aro AR, Holli KA, Schreck M, Peura A, Joensuu HT. A short
communication course for physicians improves the quality of patient
information in a clinical trial. Acta Oncol. 2007;46:42–8.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Dellson et al. Trials          (2019) 20:301 Page 10 of 10
